Human Metabolome Technologies Inc

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Human Metabolome Technologies Inc has already paid €0.0994 in dividends. The last payout was in September.

Financials

In the last quarter, Human Metabolome Technologies Inc had revenue of €1.7m and net profit of €186.63k

(EUR)	June 2026	YoY
Revenue	1.7m	52.07%
Gross profit	909.36k	105.52%
Net profit	186.63k	165.90%
EBITDA	158.31k	135.61%

Fundamentals

Metric	Value
Market capitalization	€17.76m
Number of shares	5.42m
52-week high/low	€4.31 - €3.21
Dividend yield	3.02%
Dividends TTM	€0.0994
Beta	1.50
P/E ratio	16.08
PEG ratio	-0.95
P/B ratio	1.74
P/S ratio	2.22

Company profile

Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays, flux analysis, and lipidomics services. It also develops biomarkers, such as Phosphorylethanolamine, a biomarker for major depressive disorder and measured in blood plasma. The company offers solutions for cancer metabolism, metabolic flux analysis, infectious diseases, basic science, preclinical and clinical, food and nutrition, and microbiome applications. It has a collaboration with the Institute for Advanced Biosciences and Keio University for the development of metabolome analysis technology. The company was incorporated in 2003 and is based in Tsuruoka, Japan.